Long-term collaboration for U.S. distribution of Tryton Side Branch Stent pending regulatory approval. “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions.” DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies …
Outcomes from Tryton Medical Pivotal Confirmatory Study Published in JACC Cardiovascular Interventions
Study met primary endpoint, results confirm safety profile for treatment of coronary bifurcation lesions involving large side branches “Bifurcation lesions are a common challenge for interventional cardiologists, present in 20%-30% of coronary lesions treated with percutaneous coronary intervention” DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results from the …
Tryton Medical Files Pre-Market Approval Application with US FDA for Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Application is supported by results from the pivotal Tryton Confirmatory Study in the treatment of significant coronary bifurcation lesions. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug …
Tryton Meets Primary Endpoint in Pivotal Confirmatory Study of Tryton Side Branch Stent in Treatment of Coronary Bifurcation Lesions
Dateline City: DURHAM, N.C. Positive results presented at Transcatheter Cardiovascular Therapeutics symposium support planned PMA submission. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced results from the pivotal Tryton Confirmatory Study confirming the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions …
Tryton Medical to Present Pivotal Clinical Data on Dedicated Bifurcation Stent at TCT 2015
Dateline City: DURHAM, N.C. Company will host lunch symposium to highlight implications of findings on treatment of coronary bifurcation lesions on Tuesday, October 13th at 11:30am PDT. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the company will present results from the Tryton Confirmatory Study, a pivotal single-arm clinical trial …
Tryton Medical Announces Publication of Post Hoc Analysis of Randomized Clinical Trial in Treatment of Bifurcation Lesions using Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Analysis showed reductions in target vessel failure and improved side branch percent diameter stenosis in patients with a coronary bifurcation lesion in vessels 2.25mm in diameter or greater DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results of a post hoc analysis of the pivotal …
Tryton Medical Announces Completion of Enrollment in the EXTENDED ACCESS Registry for its Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Tryton remains on schedule to file pre-market approval application for its Side Branch Stent in 2015 DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the completion of enrollment in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. The Tryton registry is …
Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology
Dateline City: DURHAM, N.C. Results from largest study in treatment of coronary bifurcations demonstrate reductions in TVF and side branch percent stenosis in intended population of patients with complex lesions involving significant side branches DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, today announced that results from the company’s pivotal clinical trial for the …
Tryton Medical Enrolls First Patient in the EXTENDED Access Registry
Dateline City: DURHAM, N.C. A Single Arm Study Designed to Support FDA Submission for US Approval DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE …
Tryton Medical Announces Events at EuroPCR 2014 in Paris
Dateline City: DURHAM, N.C. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 20-23, 2014 in Paris. The …